Literature DB >> 34477380

Concentration-Independent Multivalent Targeting of Cancer Cells by Genetically Encoded Core-Crosslinked Elastin/Resilin-like Polypeptide Micelles.

Patrick Weber1,2,3, Michael Dzuricky2, Junseon Min2, Irene Jenkins2, Ashutosh Chilkoti2.   

Abstract

Valency is a fundamental principle to control macromolecular interactions and is used to target specific cell types by multivalent ligand-receptor interactions using self-assembled nanoparticle carriers. At the concentrations encountered in solid tumors upon systemic administration, these nanoparticles are, however, likely to show critical micelle concentration (CMC)-dependent disassembly and thus loss of function. To overcome this limitation, core-crosslinkable micelles of genetically encoded resilin-/elastin-like diblock polypeptides were recombinantly synthesized. The amphiphilic constructs were covalently photo-crosslinked through the genetically encoded unnatural amino acid para-azidophenylalanine in their hydrophobic block and they carried different anticancer ligands on their hydrophilic block: the wild-type tenth human fibronectin type III domain, a GRGDSPAS peptide-both targeting αvβ3 integrin-and an engineered variant of the third fibronectin type III domain of tenascin C that is a death receptor 5 agonist. Although uncrosslinked micelles lost most of their targeting ability below their CMC, the crosslinked analogues remained active at concentrations up to 1000-fold lower than the CMC, with binding affinities that are comparable to antibodies.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34477380      PMCID: PMC9339257          DOI: 10.1021/acs.biomac.1c00897

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.978


  67 in total

Review 1.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 2.  RGD and other recognition sequences for integrins.

Authors:  E Ruoslahti
Journal:  Annu Rev Cell Dev Biol       Date:  1996       Impact factor: 13.827

Review 3.  Monoclonal antibodies: technologies for early discovery and engineering.

Authors:  Patrick J Kennedy; Carla Oliveira; Pedro L Granja; Bruno Sarmento
Journal:  Crit Rev Biotechnol       Date:  2017-08-08       Impact factor: 8.429

4.  Integrin alpha(v)beta(3)-Targeted Cancer Therapy.

Authors:  Zhaofei Liu; Fan Wang; Xiaoyuan Chen
Journal:  Drug Dev Res       Date:  2008       Impact factor: 4.360

Review 5.  Photo-induced covalent cross-linking for the analysis of biomolecular interactions.

Authors:  George W Preston; Andrew J Wilson
Journal:  Chem Soc Rev       Date:  2013-02-11       Impact factor: 54.564

6.  Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.

Authors:  Sungho Bae; Kyungwan Ma; Tae Hyung Kim; Eun Seong Lee; Kyung Taek Oh; Eun-Seok Park; Kang Choon Lee; Yu Seok Youn
Journal:  Biomaterials       Date:  2011-11-25       Impact factor: 12.479

7.  Avidity and Cell Uptake of Integrin-Targeting Polypeptide Micelles is Strongly Shape-Dependent.

Authors:  Michael Dzuricky; Sinan Xiong; Patrick Weber; Ashutosh Chilkoti
Journal:  Nano Lett       Date:  2019-08-12       Impact factor: 11.189

Review 8.  Targeting tumor vasculature with homing peptides from phage display.

Authors:  E Ruoslahti
Journal:  Semin Cancer Biol       Date:  2000-12       Impact factor: 15.707

9.  Stability of Self-Assembled Polymeric Micelles in Serum.

Authors:  Jiao Lu; Shawn C Owen; Molly S Shoichet
Journal:  Macromolecules       Date:  2011-07-08       Impact factor: 5.985

10.  Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin αV β3.

Authors:  André Raposo Moreira Dias; Arianna Pina; Alberto Dal Corso; Daniela Arosio; Laura Belvisi; Luca Pignataro; Michele Caruso; Cesare Gennari
Journal:  Chemistry       Date:  2017-09-06       Impact factor: 5.236

View more
  1 in total

1.  The Two Sweet Sides of Janus Lectin Drive Crosslinking of Liposomes to Cancer Cells and Material Uptake.

Authors:  Lina Siukstaite; Francesca Rosato; Anna Mitrovic; Peter Fritz Müller; Katharina Kraus; Simona Notova; Anne Imberty; Winfried Römer
Journal:  Toxins (Basel)       Date:  2021-11-09       Impact factor: 4.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.